IRADIMED CORP (IRMD) is a globally recognized company that specializes in the invention and manufacture of non-magnetic Intravenous (IV) infusion pump systems. These products are specifically designed for use in Magnetic Resonance Imaging (MRI) environments. Founded in 1992 and headquartered in Winter Springs, Florida, USA, the company became publicly traded on the NASDAQ in 2014 under the ticker symbol IRMD.
The primary offerings of IRADIMED include the MRidium® MRI compatible IV infusion pump system that has a non-magnetic ultrasonic motor and specially designed non-ferrous parts and accessories, allowing it to be safely and accurately operated in the MRI environment. This innovative product made a significant contribution to patient safety by allowing constant infusion therapy for patients undergoing MRI procedures.
Besides the MRidium® IV pump, IRADIMED also developed MRI compatible patient vital signs monitoring systems, which is a crucial part of patient care during MRI procedures. These innovative products, being MRI-safe and non-magnetic, provide seamless patient care in a challenging and complex magnetic environment.
The company's business model is centered on research, development, sales, and marketing. While the majority of its revenue comes from the United States, IRADIMED is expanding its global footprint with a growing presence in Europe, Asia, the Middle East, and Latin America.
IRADIMED displays a continued commitment to innovation and quality, reflecting in their commitment to obtaining necessary regulatory approvals and certifications for its products. The company's ISO 13485:2016 certification attests to its rigorous adherence to quality management requirements for medical devices.
The company's core vision is to improve and save lives by creating innovative, state-of-the-art medical equipment that leads to safer and more effective patient care. With a robust approach to research and development, combined with a dedicated team and strong leadership, IRADIMED continues to pave the way in non-magnetic medical device technology.
In recent years, IRADIMED has marked success with a steady increase in annual revenues, showcasing its value in a growing healthcare market. Recognized for its market-driven products and contributions towards patient care, IRADIMED's industry leadership in MRI compatible medical technologies is remarkable. Its commitment to innovation and focus on research and development will likely propel the company further into industry leadership, reflecting in its stock market performance.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
IRADIMED (IRMD) shares have gained attention following the release of their third-quarter 2026 results, new guidance, and a reaffirmed dividend. While the stock has seen a recent 3.57% gain, its 30-day and year-to-date returns are down, contrasting with strong longer-term performance. The article explores different valuation perspectives, including an "undervalued" narrative based on a new MRI-compatible IV pump and a "P/E lens" view suggesting the stock is richly valued.
iRadimed (NASDAQ: IRMD) reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase, primarily driven by strong sales and ramped production of its new 3870 MR IV pump and 3880 monitor. The company achieved GAAP earnings of $0.51 per share and non-GAAP earnings of $0.55 per share, with gross margins improving to 76%. Management expressed confidence in continued growth, expecting double-digit revenue increases for 2027 and a strong finish to 2026, with Q4 revenue projected between $25 million and $26.5 million.
IRadimed Director Joe Kiani acquired 698 shares of common stock on September 23, 2026, through the vesting of restricted stock units. This transaction, detailed in a Statement of Changes in Beneficial Ownership, is the first installment under the company's 2023 Equity Incentive Plan. Following the vesting, Kiani directly holds 698 shares of common stock and 1,397 remaining RSUs.